Compare Cytokinetics Inc (CYTK) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 2.9× Cytokinetics Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| CYTK | RPRX | |
|---|---|---|
Market Cap | $8.62B | $25.27B |
Volume | 2,594,626 | 3,671,183 |
Sector | Health | Health |
52-Week High | $87.26 | $63.96 |
52-Week Low | $54.76 | $35.44 |
Typical Hold Time | 19 Days | 1 Days |
Enterprise Value | $8.72B | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.91, up 2.93% with bearish technical signals despite strong analyst support. The company shows promising drug development with positive Phase 3 results for aficamten in HCM treatment, though fundamentals remain challenged with a P/S ratio of 114 and negative profit margins. Recent executive stock sales and high cash burn from operations highlight ongoing financial pressures despite growing revenue potential from new drug launches.
The outlook balances significant upside potential from analyst price targets averaging $112.60 against substantial execution risks. While clinical successes position CYTK for growth in cardiovascular treatments, persistent losses and high valuation metrics require careful risk assessment. The stock offers speculative growth opportunity but demands close monitoring of commercialization progress and path to profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
